X-TOLE2: Clinical trial of a new drug for focal epilepsy

Focal epilepsy is a condition associated with seizures arising from a specific part of the brain.  Available anti-epileptic medications and other treatments are able to control seizure activity in the majority of patients.  In some patients, however, seizures are not adequately controlled by standard therapies.

This study is trialing a novel anti-epileptic medication called XEN1101 in focal epilepsy patients who have not achieved satisfactory seizure control on at least two anti-epileptic medications.  
The study evaluates the safety and effectiveness of XEN1101 for reducing the frequency of seizure. s XEN1101 acts through a different mechanism of action to approved anti-epilepsy drugs, and therefore has potential to control seizures in patients who failed to respond to standard therapies.
 

Category
Trial Status
Recruiting
Trial Phase
Phase 3 Drug Trial
Registry Listing
ERM Project ID
94623
Trial contact details
Contact Person
Delphine Levy-Bencheton, Clinical Trial Coordinator
What you need to know

Who can take part?

You may be eligible to participate in this study if you:
•    Are 18 years of age or older
•    Have been diagnosed with focal epilepsy
•    Have tried two or more anti-epileptic medications but did not achieve sustained freedom from seizures

People with certain medical conditions or taking a small number of medications may be ineligible for this study..  People who are considering becoming a mother or father during the study are not eligible to participate.  The study staff will discuss the conditions with you if you are interested in taking part. in the study. 
 

What is involved for you?

Study participants will be randomly assigned to receive one of two dose levels of the study drug or placebo in addition to their existing anti-epileptic medications, for a period of 3 months. Neither you, nor the Mater clinical trial team will know whether you are receiving study drug or placebo.  This is necessary to provide strong scientific evidence regarding drug effects.  Participants who complete the trial will be invited to participate in an “open label” extension study (3 years), in which all participants receive the investigational medication.

Participants will also undertake the following procedures, tests and assessments:
•    Physical exam and medical history
•    Neurological exams
•    Eye exams
•    Health and wellbeing questionnaires  
•    Electrocardiograms (ECG)
•    Pregnancy tests if applicable
•    Blood tests
•    Urine tests
•    Keep a seizure diary
 

All research clinical trials news

A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.

07

May

Technology shines a light on better bladder cancer detection

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Displaying results 1-3 (of 19)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|